Características clínicas y supervivencia de los pacientes nunca fumadores con cáncer de pulmón / Clinical Characteristics and Survival in Never Smokers With Lung Cancer

Introducción y objetivo: Analizar la frecuencia, las características clínicas y la supervivencia de los pacientes con cáncer de pulmón nunca fumadores comparándolas con los pacientes fumadores. Pacientes y métodos: Estudio retrospectivo de pacientes diagnosticados de cáncer de pulmón mediante citohistología de 1999 al 2011. Se estimó la supervivencia por el método de Kaplan-Meier. Para estimar la relación entre las variables se usó la prueba de χ2. Resultados: Se diagnosticaron 2.161 pacientes, 396 (18,3%) nunca fumadores. En este grupo la edad media (± desviación estándar) fue de 72,85 ± 10,52, el 64,6% mujeres y el 35,4% hombres. Según la citohistología, el 55,6% eran adenocarcinoma, el 20,5% epidermoide, el 15% de célula pequeña, el 2,7% de célula grande y el 6,2% otros subtipos. El diagnóstico se hizo en estadio avanzado ( IV ) en el 61,4% de pacientes, y el 14,4% recibieron tratamiento quirúrgico. La supervivencia fue del 12,4%, sin diferencias entre los 2 grupos. En el grupo de nunca fumadores las mujeres tuvieron mejor supervivencia que los hombres. Conclusiones: El 18,3% fueron pacientes nunca fumadores. Se diagnosticaron mayoritariamente en mujeres, estadios avanzados y estirpe histológica adenocarcinoma. No hubo diferencias de supervivencia con el grupo de fumadores

Introduction and objective: To analyze the frequency, clinical characteristics and survival of patients with lung cancer (LC) who have never smoked in comparison to patients who smoke. Patients and methods: A retrospective study in patients diagnosed with LC by cytohistology between 1999 and 2011. Survival was estimated by the Kaplan-Meier method. The χ2 test was used to estimate the relationship between the variables. Results: A total of 2161 patients were diagnosed with LC, 396 (18.3%) of whom had never smoked. The mean age (±standard deviation) in this group was 72.85±10.52; 64.6% were women and 35.4% men. According to the cytohistology, 55.6% were adenocarcinoma, 20.5% squamous cell, 15% small cell, 2.7%large cell and 6.2% other subtypes. The diagnosis was made in advanced stage (IV) in 61.4%, and 14.4% of the patients received surgical treatment. Survival was 12.4%, with no differences between the two groups. In the group of never smokers, women had better survival than men. Conclusions: Of the patients diagnosed with LC, 18.3% had never smoked. It was diagnosed mainly in women, at advanced stages and the most common histological type was adenocarcinoma. There were no survival differences compared to the group of smokers

Clinical characteristics and survival in never smokers with lung cancer.

INTRODUCTION AND OBJECTIVE: To analyze the frequency, clinical characteristics and survival of patients with lung cancer (LC) who have never smoked in comparison to patients who smoke. PATIENTS AND METHODS: A retrospective study in patients diagnosed with LC by cytohistology between 1999 and 2011. Survival was estimated by the Kaplan-Meier method. The χ(2) test was used to estimate the relationship between the variables. RESULTS: A total of 2161 patients were diagnosed with LC, 396 (18.3%) of whom had never smoked. The mean age (±standard deviation) in this group was 72.85±10.52; 64.6% were women and 35.4% men. According to the cytohistology, 55.6% were adenocarcinoma, 20.5% squamous cell, 15% small cell, 2.7% large cell and 6.2% other subtypes. The diagnosis was made in advanced stage (iv) in 61.4%, and 14.4% of the patients received surgical treatment. Survival was 12.4%, with no differences between the two groups. In the group of never smokers, women had better survival than men. CONCLUSIONS: Of the patients diagnosed with LC, 18.3% had never smoked. It was diagnosed mainly in women, at advanced stages and the most common histological type was adenocarcinoma. There were no survival differences compared to the group of smokers.

Síndrome de apnea-hipopnea del sueño en pacientes normopeso: características y comparación con pacientes con sobrepeso y obesidad / Obstructive Sleep Apnea in Normal Weight Patients: Characteristics and Comparison With Overweight and Obese Patients

Objetivo: Conocer la frecuencia del síndrome de apnea-hipopnea del sueño (SAHS)y del síndrome metabólico (SM) en normopeso y sus características. Determinar si existen diferencias epidemiológicas con aquellos con sobrepeso u obesidad. Métodos: Se estudiaron todos los pacientes con sospecha de SAHS remitidos al laboratorio del sueño desde enero a diciembre 2009. Se diagnosticó de SAHS cuando el índice de apnea-hipopnea (IAH) era > 5 y existía clínica. Se diagnosticó el SM según los criterios de la International Diabetes Federation (IDF). Los pacientes se distribuyeron en 3 grupos según el índice de masa corporal (IMC): normopeso (< 25 kg/m2), sobrepeso (25-29,9 kg/m2) y obesidad (≥ 30 kg/m2). Resultados: Se estudiaron 475 pacientes: 7,60% normopeso y 56,40% obesos. De los normopeso, la mayoría eran mujeres, roncadores, no fumadores, no consumían alcohol y eran significativamente más jóvenes y con menor perímetro de cuello y abdomen. Se diagnosticó de SAHS al 90,10%: normopeso 77,70%. En pacientes con SAHS y normopeso la mayoría eran SAHS leve, existiendo diferencias entre diagnóstico de SAHS e IMC categorizado. Se diagnosticó de SM al 64,40%: 33,33% normopeso, encontrando mayor probabilidad de SM al aumentar el IMC. La prevalencia de SAHS y SM simultáneamente en normopeso fue del 22% y en obesos del 70,52%. El SAHS en normopeso se relacionó con el sexo y la edad. No se encontró relación entre SM y SAHS, y tampoco entre malformación otorrinolaringológica y SAHS. Se trató con CPAP a 8 pacientes normopeso con SAHS. Conclusiones: La frecuencia de SAHS en normopeso era menor que en los sobrepeso y obesos. La frecuencia de SAHS y SM simultáneamente en normopeso frente a obesos fue menor. Los pacientes normopeso eran con más frecuencia mujeres, más jóvenes y sin hábitos tóxicos. Los factores predictores de SAHS en normopeso eran sexo y edad, sin que existiera relación entre SM y SAHS (AU)

Objective: To determine the frequency of obstructive sleep apnoea (OSA) and metabolic syndrome (MS) in normal weight patients and their characteristics, and to compare these with overweight and obese patients. Methods: We studied all patients with suspected OSA referred to the sleep laboratory from January to December 2009. OSA was diagnosed when the apnoea-hypopnoea index (AHI) was >5 and symptoms were present. MS was diagnosed according to International Diabetes Federation (IDF) criteria. The patients were distributed into 3 groups according to body mass index (BMI): normal weight (<25 kg/m2), overweight (25–29.9 kg/m2) and obese (≥30 kg/m2). Results: We studied 475 patients: 7.60% normal weight and 56.4% obese. Most patients in the normal weight group were women, snorers, non-smokers, non-drinkers and were significantly younger and with a smaller neck and waist circumference than obese and overweight patients. OSA was diagnosed in 90.10%: 77.70% normal weight. OSA in these patients was mostly mild, and there were differences between the diagnosis of OSA and the BMI classified. MS was diagnosed in 64.40%: 33.33% normal weight. There was a higher probability of MS as the BMI increased. OSA and MS frequency in normal weight patients was 22% and in obese patients was 70.52%. OSA in normal weight patients was related with gender and age. There was no relationship between OSA and MS, or between otorhinolaryngological malformations and OSA in normal weight patients. Eight normal weight patients with OSA were treated with continuous positive airway pressure (CPAP) therapy. Conclusions: The frequency of OSA in normal weight patients was lower than in overweight and obese patients. The frequency of concomitant OSA and MS was lower in normal weight patients than in obese subjects. Normal weight patients were mostly women, younger and had no toxic habits. In normal weight patients, age and gender were predictive factors for OSA, but OSA and MS were not related (AU)

Obstructive sleep apnea in normal weight patients: characteristics and comparison with overweight and obese patients.

OBJECTIVE: To determine the frequency of obstructive sleep apnoea (OSA) and metabolic syndrome (MS) in normal weight patients and their characteristics, and to compare these with overweight and obese patients. METHODS: We studied all patients with suspected OSA referred to the sleep laboratory from January to December 2009. OSA was diagnosed when the apnoea-hypopnoea index (AHI) was >5 and symptoms were present. MS was diagnosed according to International Diabetes Federation (IDF) criteria. The patients were distributed into 3 groups according to body mass index (BMI): normal weight (<25kg/m(2)), overweight (25-29.9kg/m(2)) and obese (≥30kg/m(2)). RESULTS: We studied 475 patients: 7.60% normal weight and 56.4% obese. Most patients in the normal weight group were women, snorers, non-smokers, non-drinkers and were significantly younger and with a smaller neck and waist circumference than obese and overweight patients. OSA was diagnosed in 90.10%: 77.70% normal weight. OSA in these patients was mostly mild, and there were differences between the diagnosis of OSA and the BMI classified. MS was diagnosed in 64.40%: 33.33% normal weight. There was a higher probability of MS as the BMI increased. OSA and MS frequency in normal weight patients was 22% and in obese patients was 70.52%. OSA in normal weight patients was related with gender and age. There was no relationship between OSA and MS, or between otorhinolaryngological malformations and OSA in normal weight patients. Eight normal weight patients with OSA were treated with continuous positive airway pressure (CPAP) therapy. CONCLUSIONS: The frequency of OSA in normal weight patients was lower than in overweight and obese patients. The frequency of concomitant OSA and MS was lower in normal weight patients than in obese subjects. Normal weight patients were mostly women, younger and had no toxic habits. In normal weight patients, age and gender were predictive factors for OSA, but OSA and MS were not related.

Tratamiento con drenajes subcutáneos en el neumomediastino y enfisema subcutáneo masivo / Treatment With Subcutaneous Drainage in the Pneumomediastinum and Massive Subcutaneous Emphysema

No disponible

Lung cancer in women: a comparison with men and an analysis of cases diagnosed in Ourense (Spain) 1999-2006.

INTRODUCTION AND OBJECTIVE: To analyse frequency, characteristics and survival of women with lung cancer (LC), in contrast to male patients. PATIENTS AND METHODS: A retrospective study was performed in patients with LC diagnosed by histocytology from 1999 to 2006. Survival was estimated by the Kaplan-Meier method. The chi-squared test was used to compare variables. RESULTS: A total of 1,290 patients were diagnosed, 190 (14.7%) of them were women, with a mean age of 67±13 years. The percentage of smokers was 17%. Histological types: adenocarcinoma 53%, small cell 21%, squamous cell carcinoma 13%. Surgery was performed (20%) in a higher percentage of women than in men. There were no differences in survival between the two groups. CONCLUSIONS: Of the total cases diagnosed, 14.7% were women, with a lower percentage of smokers. Adenocarcinoma was the most common histological type in women. There was no differences in survival compared to men.

Cáncer de pulmón en mujeres, comparativo con hombres: análisis de los casos diagnosticados en el Complexo Hospitalario de Ourense entre 1999 y 2006 / Lung Cancer in Women: a Comparison with Men and an Analysis of Cases Diagnosed in Ourense (Spain) 1999–2006

Introducción y objetivoAnalizar la frecuencia, las características y la supervivencia de las mujeres con cáncer de pulmón (CP), comparándolas con los pacientes varones.Pacientes y métodosEstudio retrospectivo de pacientes diagnosticados de CP mediante citohistología del 1999 al 2006. Se estimó la supervivencia por el método de Kaplan-Meier. Para estimar la relación entre las variables se usó la prueba de chi-cuadrado.ResultadosSe diagnosticaron 1.290 pacientes, el 14,7% mujeres. En el grupo de mujeres la edad media (± desviación estándar) fue de 67±13 años. Eran fumadoras el 17%. Según la citohistología, el 53% eran adenocarcinomas, 21% célula pequeña y 13% epidermoide. Se realizó cirugía (20%) en mayor porcentaje que en los varones. No hubo diferencias de supervivencia con el grupo de los hombres.ConclusionesEl 14,7% de los casos fue diagnosticado en mujeres, siendo el porcentaje de fumadoras menor. La estirpe histológica más frecuente es adenocarcinoma. No hubo diferencias de supervivencia con el grupo de los hombres(AU)

Introduction and objectiveTo analyse frequency, characteristics and survival of women with lung cancer (LC), in contrast to male patients.Patients and methodsA retrospective study was performed in patients with LC diagnosed by histocytology from 1999 to 2006. Survival was estimated by the Kaplan-Meier method. The chi-squared test was used to compare variables.ResultsA total of 1,290 patients were diagnosed, 190 (14.7%) of them were women, with a mean age of 67±13 years. The percentage of smokers was 17%. Histological types: adenocarcinoma 53%, small cell 21%, squamous cell carcinoma 13%. Surgery was performed (20%) in a higher percentage of women than in men. There were no differences in survival between the two groups.ConclusionsOf the total cases diagnosed, 14.7% were women, with a lower percentage of smokers. Adenocarcinoma was the most common histological type in women. There was no differences in survival compared to men(AU)

Repression and coping styles in asthmatic patients.

The objectives of this study were to (a) determine prevalence of the dispositional repressive coping style as well as other situational coping styles in a sample of asthmatic patients and (b) to analyze the capacity of these styles to predict subsequent morbidity (emergency room visits or hospitalizations due to asthma) during a 12-month follow-up. A sample of 75 adult asthmatic patients was selected and information about sociodemographics, asthma severity, and patient's perception of illness severity was collected. Repressive coping style was defined by a combination of scores obtained on the Trait Anxiety Inventory and the Marlowe-Crowne Social Desirability Scale. Coping styles were assessed with the dispositional version of the Coping Orientation to Problems Experienced Inventory. Eighteen patients (24%) were classified as repressors. Repressor asthmatics obtained scores significantly lower on Emotion-Focused Coping compared to non-repressors (F ((1,72)) = 5.15, p = .026). Patients who perceived their asthma as severe reported to use Emotion-Focused Coping more than those who judged it as mild or moderate (F ((2,71)) = 4.83, p = .011). A higher use of Denial (an Emotion-Focused strategy of coping) explained 8% of variance of the frequency of emergency room visits during the 12-month follow-up. The prevalence of repressive coping style in the asthmatic population is similar to that registered in other populations of chronic patients, and it is also associated with the tendency to report a lower use of strategies traditionally considered as maladaptive. The use of Emotion-Focused Coping strategies seems to be related to a worse perception of the physical status, and among this group of strategies, Denial also could favor a poor clinical course in bronchial asthma.

Cáncer de pulmón y EPOC: una asociación frecuente / Lung Cancer and COPD: a Common Combination

Introducción y objetivoAnalizar la frecuencia, las características y la supervivencia de los pacientes con cáncer de pulmón (CP) y enfermedad pulmonar obstructiva crónica (EPOC), comparándolas con las de pacientes sin EPOC.Material y métodosSe ha realizado un estudio retrospectivo de pacientes diagnosticados de CP mediante citohistología. Se estimó la supervivencia por el método de Kaplan-Meier. El análisis estadístico se realizó con el programa SPSS 15.0.ResultadosSe diagnosticó de CP a 996 pacientes, el 39,8% con EPOC. La edad media (± desviación estándar) de estos últimos era de 70±9,19 años. En cuanto a los estadios GOLD, el 18,2% se encontraba en estadio I, el 53,6% en estadio II, el 24% en estadio III y el 4,2% en estadio IV. Según la citohistología, el 48,2% de los CP eran escamosos, el 22% adenocarcinomas y el 22,5% microcíticos. La supervivencia fue mayor en el grupo con EPOC.ConclusionesEl CP y la EPOC se asocian en un 39,8% de los casos. La estirpe más frecuente del CP es la escamosa y la supervivencia es mayor en el grupo con EPOC(AU)

Background and objectiveTo analyse frequency, characteristics and patient survival with lung cancer (LC) and COPD, comparing them with patients without COPD.Material and methodsA retrospective study, of patients diagnosed by means of cytohistology. Survival was estimated by the Kaplan-Meier method. The statistical analysis was carried out using SPSS 15.0.ResultsA total of 996 patients were diagnosed, 39.8% COPD. Mean age70±9.19 years. GOLD stages: I 18.2%, II 53.6%, III 24%, IV 4.2%. The histological types: squamous cell carcinoma 48.2%, adenocarcinoma 22%, small cell carcinoma 22.5%. Survival was longer in the COPD group.ConclusionsLC and COPD are combined in 39.8%. Squamous cell type is more frequent and survival was longer in the COPD group(AU)

[Lung cancer and COPD: a common combination]. / Cáncer de pulmón y EPOC: una asociación frecuente.

BACKGROUND AND OBJECTIVE: To analyse frequency, characteristics and patient survival with lung cancer (LC) and COPD, comparing them with patients without COPD. MATERIAL AND METHODS: A retrospective study, of patients diagnosed by means of cytohistology. Survival was estimated by the Kaplan-Meier method. The statistical analysis was carried out using SPSS 15.0. RESULTS: A total of 996 patients were diagnosed, 39.8% COPD. Mean age 70+/-9.19 years. GOLD stages: I 18.2%, II 53.6%, III 24%, IV 4.2%. The histological types: squamous cell carcinoma 48.2%, adenocarcinoma 22%, small cell carcinoma 22.5%. Survival was longer in the COPD group. CONCLUSIONS: LC and COPD are combined in 39.8%. Squamous cell type is more frequent and survival was longer in the COPD group.